Stephen Yoder
Chief Executive Officer bei PIERIS PHARMACEUTICALS, INC.
Vermögen: 1 098 $ am 31.03.2024
Ursprung des Netzwerks ersten Grades von Stephen Yoder
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 30 | |
12
| Public Company | Biotechnology | 12 |
Pieris Pharmaceuticals GmbH
 Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The private company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder.
1
| Subsidiary | Biotechnology | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Stephen Yoder
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| JUNIPER PHARMACEUTICALS INC | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Chief Tech/Sci/R&D Officer | |
| GT BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
| TRANSGENE | Biotechnology | Director/Board Member Director/Board Member | |
Citigroup Alternative Investments LLC
 Citigroup Alternative Investments LLC Investment ManagersFinance Citigroup Alternative Investments LLC (CAI) is a SEC-registered asset management firm headquartered in New York City. The firm was founded in 2002 and is a wholly-owned subsidiary of Citigroup Investments, Inc., which is owned by Citigroup, Inc. (NYSE: C). CAI provides advisory services to private investment companies, such as private equity funds and funds of one or more private equity and real estate funds. The investors in the funds advised by the firm are institutional investors, funds of funds, high-net worth individuals and employees, and former employees of Citigroup, Inc. | Investment Managers | Portfolio Manager-Equities | |
| SANOFI | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Operating Officer | |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Biotechnology | Director/Board Member | |
Lombard Odier Asset Management (USA) Corp.
 Lombard Odier Asset Management (USA) Corp. Investment ManagersFinance Lombard Odier Asset Management (USA) Corp. (LOAM) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2000 and do-business-as Lombard Odier Investment Managers. The firm is a subsidiary of LO Holding SA and their ultimate parent is Switzerland-based Compagnie Lombard Odier SCmA. LOAM provides investment advisory services on a discretionary basis to private pooled investment vehicles (Funds) and investment advisory accounts. The investors in the Funds consist of endowments, foundations, insurance companies, high net-worth individuals, funds of funds, public and corporate pensions, and other sophisticated investors. | Investment Managers | Portfolio Manager-Equities | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Toronto | College/University | Doctorate Degree | |
| University of Western Ontario | College/University | Undergraduate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Corporate Officer/Principal | |
| Universität zu Köln | College/University | Doctorate Degree | |
| Technische Universität Darmstadt | College/University | Doctorate Degree Graduate Degree | |
| AMBRX INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| SUCAMPO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Polpharma Biologics Utrecht BV
 Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree | |
| University of Regensburg | College/University | Undergraduate Degree Doctorate Degree | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
Intermediate Capital Group Plc (Private Equity)
 Intermediate Capital Group Plc (Private Equity) Investment ManagersFinance Intermediate Capital Group Plc (Private Equity) (ICG) is a private equity division of Intermediate Capital Group Plc founded in 1989. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member | |
Resolve Therapeutics LLC
 Resolve Therapeutics LLC BiotechnologyHealth Technology Resolve Therapeutics LLC operates as a biotechnology company. It engages in the development of biotechnology drugs. The firm specializes in treatment of debilitating autoimmune diseases such as Systemic Lupus Erythematous and Sjogren’s syndrome. The company was founded by James Posada in 2010 and is headquartered in Seattle, WA. | Biotechnology | Chairman | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Max Planck Institute for Metals Research | College/University | Doctorate Degree | |
Lanthio Pharma BV
 Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Medical Specialties | Director/Board Member | |
| CUE BIOPHARMA, INC. | Biotechnology | Director/Board Member | |
V-Bio Ventures BV
 V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Investment Managers | Founder | |
| NEXTCURE, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
| FOGHORN THERAPEUTICS INC. | Biotechnology | Director of Finance/CFO | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Biotechnology | Chief Executive Officer | |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Investment Managers | Private Equity Investor | |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Packaged Software | Director/Board Member | |
| PRIME MEDICINE, INC. | Biotechnology | Director of Finance/CFO |
Statistik
International
| Vereinigte Staaten | 26 |
| Deutschland | 6 |
| Niederlande | 6 |
| Vereinigtes Königreich | 3 |
| Frankreich | 3 |
Sektoral
| Health Technology | 25 |
| Finance | 11 |
| Consumer Services | 9 |
| Technology Services | 3 |
| Commercial Services | 3 |
Operativ
| Director/Board Member | 170 |
| Corporate Officer/Principal | 92 |
| Independent Dir/Board Member | 55 |
| Chairman | 37 |
| Director of Finance/CFO | 36 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Daniel Camus | 31 |
| Peter Kiener | 25 |
| James Geraghty | 25 |
| Darlene M. Deptula-Hicks | 24 |
| Jean Bizzari | 24 |
| Julian Adams | 22 |
| Hans Jörg Reinhardt | 20 |
| Michael Richman | 16 |
| Matthew Sherman | 16 |
| Steven Prelack | 15 |
| Metin Colpan | 14 |
| Christina Takke | 14 |
| Allan Reine | 14 |
| Lance Thibault | 11 |
- Börse
- Insiders
- Stephen Yoder
- Unternehmensverbindungen
